David J Bearss

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Anupam Verma, D. Bearss, S. Warner, 2011, ACS medicinal chemistry letters.

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Haiyong Han, D. V. Von Hoff, R. Nagle, 2004, Molecular cancer therapeutics.

Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents.

Yong Xu, David Vollmer, Raymond Schuch, 2013, ACS medicinal chemistry letters.

High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

D. Bearss, S. Warner, H. Vankayalapati, 2013, Journal of medicinal chemistry.

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Haiyong Han, D. V. Von Hoff, R. Nagle, 2002, Cancer research.

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Haiyong Han, D. V. Von Hoff, D. Bearss, 2002, Molecular cancer therapeutics.

Structure-based design of novel anti-cancer agents targeting aurora kinases.

D. Bearss, D. Mahadevan, H. Vankayalapati, 2003, Current medicinal chemistry. Anti-cancer agents.